Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics
SRPT Price/Volume Stats
| Current price | $117.70 | 52-week high | $159.89 |
| Prev. close | $118.31 | 52-week low | $55.25 |
| Day low | $117.35 | Volume | 196,470 |
| Day high | $118.69 | Avg. volume | 997,133 |
| 50-day MA | $126.89 | Dividend yield | N/A |
| 200-day MA | $111.24 | Market Cap | 11.05B |
SRPT Stock Price Chart Interactive Chart >
Sarepta Therapeutics, Inc. (SRPT) Company Bio
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.
Latest SRPT News From Around the Web
Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.
3 Things About Sarepta Therapeutics Every Smart Investor KnowsMastering this stock requires appreciating a few scientific nuances. |
15 Best Fast Growth Stocks to Buy NowIn this article, we will take a look at the 15 best fast growth stocks to buy now. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Best Fast Growth Stocks to Buy Now. Vanguard Growth ETF is one of the most famous growth focused […] |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the DayFluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article. |
Sarepta Therapeutics Seen Expanding Duchenne Treatment LabelSarepta Therapeutics may be on the cusp of expanding the label for its Duchenne Muscular Dystrophy treatment, according to Mizuho analyst Uy Ear. The company has submitted an efficacy supplement to the FDA for Elevidys, requesting expanded approval for all DMD patients. The treatment's current label restricts its use to 4- to 5-year-old ambulatory patients. |
SRPT Price Returns
| 1-mo | -4.35% |
| 3-mo | 0.56% |
| 6-mo | 4.16% |
| 1-year | -6.00% |
| 3-year | 63.93% |
| 5-year | 0.91% |
| YTD | 22.06% |
| 2023 | -25.58% |
| 2022 | 43.90% |
| 2021 | -47.18% |
| 2020 | 32.12% |
| 2019 | 18.24% |
Continue Researching SRPT
Want to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...